echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > What cancers can a "Trojan Horse" ADC drug that kills cancer cells?

    What cancers can a "Trojan Horse" ADC drug that kills cancer cells?

    • Last Update: 2020-06-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Several drugs have been initially used in clinical practice, and many clinical studies are being carried outJamAA Oncology, a sub-journal of the American Medical Association, recently gave a brief inventory of the promising drugsscreenshot source: JAMA Oncology's websitethe composition and action of antibody drug conjugate
    ADC is usually composed of three parts: specific antibodies that can target cancer cells, proteins that act as a connecting effect, and cytotoxic chemical molecules attached to antibodiesWhen the antibody binds to a receptor specific to the surface of the cancer cell, it is "swallowed" into the body by the cancer cells and releases cytotoxic drugs in the cancer cells, which can killon the one hand, ADCs are expected to be used in a variety of cancer treatments because antibodies bind to the target parts of cancer cells that can be personalizedOn the other hand, cytotoxic drugs contained in ADCs are often too "firepower" to be delivered alone, which reduces the damage to healthy cells caused by cytotoxic drugssuch drugs are usually administered intravenouslypossible side effects
    the side effects of the drug vary depending on the targeting of cancer cell receptors and the cytotoxic drugs containedThe most common adverse reactions may be that cytotoxic drugs are released into the blood early before aDC is swallowed into cancer cells, causing red blood cells, white blood cells, platelet counts, etc., peripheral neuropathy, liver damage and vision changesantibody drug conjugate is made up of three parts that target specific cancer cells and "sneak in" to release drugs (Photo: Source: Supplied)currently used in cancer treatment
    5 ADCs have been approved for the treatment of blood cancer or breast cancerMylotarg (Gemtuzumab ozogamicin): Has been approved by the FDA and the European Union for use in acute myeloid leukemia (AML)The drug targets CD33 receptors expressed on the surface of myelin cells, and CD33 is present in up to 90% of AML patientsAdcetris(Brentuximab vedotin): Target CD30 receptor, which has been approved by the FDA for use in some patients with classic Hodgkin's lymphoma and metalysis large cell lymphomaBesponsa: Target CD22 receptor, which has been approved by the FDA for use in B-cell precursor acute lympholeukemia leukemiaPolatuzumab vedotin-piiq: Target CD79b receptor, approved by the FDA in conjunction with chemotherapy protocols for recurrent diffuse large B-cell lymphoma (the most common non-Hodgkin lymphoma)The FDA has noted that this is the first immunochemotherapy to be used for the diseaseIn a Phase 1b/2 clinical trial, patients treated with Polivy and standard therapy (benzoistin and rituximab) had more than double the total remission rate (40 percent vs18 percent) compared to the standard treatment group aloneKadcyla (ado-trastuzumab emtansine): Contains the single anti-drug ingredient qutoberida, targeted at HER2 protein, approved by the FDA for HER2-positive early breast cancer aid therapy and metastatic breast cancer treatmentat the same time as the drug's future, nearly 60 more are being studied in nearly 600 clinical trials in aDCThe new generation of ADCs has also improved the design of drugs such as ADC connectivity proteins and cytotoxic drug release mechanismsblood cancers, including leukemia and lymphoma, remain the target of most ADCs, but a growing number of new generations of ADCs are exploring the use of solid tumors such as breast cancer, colorectal cancer, lung cancer, prostate cancer, ovarian cancer, and urinary tract cancerFor example, an ADC called tisotumab vedotin showed therapeutic prospects in early clinical trials in six different cancer patients earlier this yearas one of the key strategies for new immunotherapy drugs and the fight against cancer, ADC is being developed around the world in the hope that more drugs will be proven in efficacy and safety for the benefit of more cancer patientsReference sAntibody Drug Conjugates for Cancer TreatmentJAMA Oncol, 10.1001/jamaoncol.2019.3552 Retrieved Oct 8, 2019, from https://
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.